Tue, Apr 29, 9:16 PM (19 days ago)
**Organogenesis Holdings Inc. (ORGO) 10-K/A Summary** **Company Overview:** Organogenesis Holdings Inc. (ORGO), listed on the Nasdaq Capital Market, is a biotechnology company focused on regenerative medicine. The amendment to the 10-K filing includes Part III, which details directors, executive officers, corporate governance, executive compensation, and related stockholder matters. **Financial Performance:** - **Revenue:** ORGO achieved net revenue of $482,000,000 in 2024, exceeding the target and exceeding levels, resulting in a 130% attainment for this metric. - **Gross Margin:** The gross margin performance objective was met at between the minimum and target levels, resulting in a 77% attainment. - **Adjusted EBITDA:** The Adjusted EBITDA performance objective was met at between the exceed and maximum levels, resulting in a 155% attainment. - **Overall Performance:** The company's overall performance with respect to these goals was at the 136% level. **Executive Compensation:** - **Base Salaries:** Increased for all named executive officers (NEOs) effective April 1, 2024. - **Annual Cash Bonuses:** Tied to corporate performance metrics, including net revenue, gross margin, and Adjusted EBITDA. - **Equity Awards:** Included stock options and restricted stock units (RSUs) with time-based vesting. - **Benefits:** Included health and welfare benefits, retirement savings, perquisites, severance, and change of control benefits. **Corporate Governance:** - **Board Committees:** Includes Audit, Compensation, and Nominating Committees, all composed of independent directors. - **Insider Trading Policy:** Prohibits short sales, hedging, and purchasing company securities on margin. - **Clawback Policy:** Requires recovery of erroneously awarded incentive-based compensation. **Risk Factors and Financial Condition:** - **Market Position:** The company's market position is influenced by its ability to innovate and compete in the regenerative medicine sector. - **Risk Factors:** Include regulatory risks, market competition, and operational challenges. **Future Outlook:** - **Strategic Overview:** Focus on aligning compensation with business objectives, individual performance, and stockholder interests. - **Future Outlook:** Continued emphasis on innovation, regulatory compliance, and market expansion. **Market Position Changes:** - **Stock Ownership:** Significant stockholders include Avista Healthcare Partners III, L.P., Organo PFG LLC, and Morgan Stanley. - **Director and Officer Ownership:** Includes beneficial ownership details for directors and executive officers. **Auditor Information:** - **Auditor:** RSM US LLP. - **Audit Fees:** $1,647,666 for fiscal 2024. **Ticker:** ORGO